Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $150

Moomoo News · Nov 8 05:37 · Ratings

Barclays analyst Balaji Prasad maintains $Ligand Pharmaceuticals (LGND.US)$ with a buy rating, and adjusts the target price from $125 to $150.

According to TipRanks data, the analyst has a success rate of 45.8% and a total average return of 3.3% over the past year.

AnalystRecentRatingAutoNews_206570_20241108_26922fcc77f9073340e6f0996aa79429a1b6f6a2_1731062002983754_mm_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $150

Risk Disclaimer